TLPO/TLPLDC Vaccine
High-risk, resected Stage III/IV Melanoma (adjuvant setting)
Phase 2bActive
Key Facts
Indication
High-risk, resected Stage III/IV Melanoma (adjuvant setting)
Phase
Phase 2b
Status
Active
Company
About Elios Therapeutics
Elios Therapeutics is a private, clinical-stage biotech company advancing personalized cancer vaccines. Its core technology platform utilizes autologous tumor lysate to create patient-specific vaccines that aim to train the immune system to recognize and destroy residual cancer cells, potentially preventing recurrence. The company's lead program, the TLPO vaccine, has progressed to Phase IIb clinical trials in high-risk melanoma, positioning it in a competitive but high-potential segment of immuno-oncology. Elios operates from Greenville, South Carolina, and appears to be in a pre-revenue, venture-backed stage of development.
View full company profile